[Drugs in oncology: an overview of benefit and refund practices in Europe]
Grössmann N, Wild C, Mayer J
Record ID 32016000989
German
Authors' objectives:
This review provides an overview of all cancer drugs approved by the European Medicines Agency (EMA) between 2009 and 2015 and the state of knowledge on patient-benefit at the time of approval, and analyses which policies for high-prized cancer drugs are applied in other (European) countries.
Authors' recommendations:
Assessments with (binding) recommendations, health economical evaluations, "Managed-Entry Agreements" and "Value-based pricing" are approaches to identify cancer drugs with the highest benefit whilst incurring acceptable costs, through transparent and traceable methods.
Details
Project Status:
Completed
URL for project:
http://eprints.hta.lbg.ac.at/1091/
Year Published:
2016
URL for published report:
http://eprints.hta.lbg.ac.at/1091/1/Rapid_Assessment_008.pdf
URL for additional information:
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie/en
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Europe
- Humans
- Internal Medicine
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.